Ashkar Areen, Awad Rania, Lesmes Uri, Sosnik Alejandro, Davidovich-Pinhas Maya
Laboratory of Food Materials Engineering, Faculty of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
Mater Today Bio. 2025 Aug 18;34:102212. doi: 10.1016/j.mtbio.2025.102212. eCollection 2025 Oct.
Oral administration is the preferred route for drug and bioactive delivery, although it raises great challenges due to the involvement of the gastrointestinal system and limited bioavailability. Herein, a novel submicron-oleogel particle system was developed using micro-structured edible oil to address the challenges associated with the low bioavailability of oral hydrophobic compounds. Oleogel particles were prepared using β-sitosterol and γ-oryzanol as oil structuring agents with dispersed dasatinib as a model drug. A particle size of approximately 160 nm and zeta-potential of around -25 mV were achieved along with a high drug entrapment efficiency of ∼90 %. analysis revealed greater stability of the submicron-oleogel particles during the gastric phase with minimal particle coalescence and significantly low dasatinib release. In the subsequent intestinal phase, the dasatinib bioaccessibility was enhanced through its integration into self-assembled mixed micelles formed during digestion. The presence of lipid byproducts and structuring agents played a crucial role in modulating this colloidal architecture and facilitating dasatinib solubilization, thereby improving its overall availability. An pharmacokinetic study confirmed enhanced dasatinib bioavailability in oil-containing formulations, attributed to improved micellization during digestion, which facilitated intestinal transport and overall absorption. Moreover, the submicron-oleogel particles displayed sustained release and absorption characteristics, attributed to the oleogel's mechanical durability. Overall, this study highlighted the enhanced therapeutic response while using oleogel particles, with a strong association between the and results. These findings underscore the potential of this novel carrier to advance the development of effective oral formulations for hydrophobic compounds.
口服给药是药物和生物活性物质递送的首选途径,尽管由于涉及胃肠系统和有限的生物利用度而带来了巨大挑战。在此,使用微结构化食用油开发了一种新型亚微米油凝胶颗粒系统,以应对口服疏水性化合物生物利用度低相关的挑战。以β-谷甾醇和γ-谷维素作为油结构化剂制备油凝胶颗粒,并将分散的达沙替尼作为模型药物。实现了约160nm的粒径和-25mV左右的zeta电位,同时药物包封效率高达约90%。分析表明,亚微米油凝胶颗粒在胃阶段具有更高的稳定性,颗粒聚结最小,达沙替尼释放显著较低。在随后的肠道阶段,达沙替尼通过整合到消化过程中形成的自组装混合胶束中而提高了生物可及性。脂质副产物和结构化剂的存在在调节这种胶体结构和促进达沙替尼溶解方面发挥了关键作用,从而提高了其总体可用性。一项药代动力学研究证实含油制剂中达沙替尼的生物利用度提高归因于消化过程中胶束化改善,这促进了肠道转运和总体吸收。此外,亚微米油凝胶颗粒表现出缓释和吸收特性,这归因于油凝胶的机械耐久性。总体而言,本研究突出了使用油凝胶颗粒时增强的治疗反应,以及体外和体内结果之间的紧密关联。这些发现强调了这种新型载体在推进疏水性化合物有效口服制剂开发方面的潜力。